DFFN Diffusion Pharmaceuticals, Inc.
Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
Company profile
Ticker
DFFN
Exchange
Website
CEO
David G. Kalergis
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Former names
Feris International, Inc., RestorGenex Corp, Stratus Media Group, Inc, Titan Motorcycle Co Of America Inc
SEC CIK
Corporate docs
IRS number
300645032
DFFN stock data
()
Investment data
Securities sold
Number of investors
Calendar
11 May 20
10 Jul 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Net income | -2.56M | -3.75M | -2.8M | -2.5M | |
| Diluted EPS | 34.51M | 2.7M | 4.69M | 3.94M | |
| Operating income | -2.96M | -2.96M | -3.05M | -2.62M | |
| Net change in cash | -3.35M | 8.04M | -2.23M | 3.04M | |
| Cash on hand | 10.83M | 14.18M | 6.14M | 8.37M | |
| Cost of revenue |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Net income | -11.8M | -18.37M | -1.36M | -18.04M | |
| Diluted EPS | 6.71M | 3.24M | -29.11 | -1.76 | |
| Operating income | -11.55M | -18.96M | -11.35M | -18.37M | |
| Net change in cash | 6.19M | -905.3K | 7.34M | -444.34K | |
| Cash on hand | 14.18M | 7.99M | 8.9M | 1.55M | |
| Cost of revenue |
Financial data from company earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 17 Jun 20 | Adams Robert W | Stock Option Common Stock | Grant | Aquire A | No | 1 | 61,300 | 61.3K | 61,300 |
| 17 Jun 20 | Cobuzzi Robert Joseph Jr. | Stock Option Common Stock | Grant | Aquire A | No | 1 | 61,300 | 61.3K | 61,300 |
| 17 Jun 20 | Giles Mark T | Stock Option Common Stock | Grant | Aquire A | No | 1 | 61,300 | 61.3K | 61,300 |
| 17 Jun 20 | Alan G Levin | Stock Option Common Stock | Grant | Aquire A | No | 1 | 61,300 | 61.3K | 61,300 |
| 7 Jan 20 | Cobuzzi Robert Joseph Jr. | RSU Common Stock | Grant | Aquire A | No | 0.51 | 98,100 | 50.03K | 98,100 |
| 7 Jan 20 | Cobuzzi Robert Joseph Jr. | Stock Option Common Stock | Grant | Aquire A | No | 0.42 | 118,600 | 49.81K | 118,600 |
Institutional ownership Q1 2020
13F holders |
Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
accelerate, Acceleration, accessible, adult, affiliated, alive, announced, authority, await, begun, clearance, confidence, costly, CTSA, decision, deliver, delivery, difficulty, discontinue, discontinued, displaying, disrupted, disruption, diversion, downturn, economy, effort, entail, environment, established, event, evolve, experienced, exposure, face, fail, fallen, fashion, feasible, flexibility, Food, governmental, guarantee, harbor, health, healthy, hemorrhagic, hierarchy, highly, hold, holder, hospital, hypoxemia, identical, ill, implement, imposed, IND, indirect, indirectly, infection, infrastructure, injury, Integrated, integrity, intention, interruption, ischemic, iTHRIV, lack, lessen, Level, lived, LLC, local, low, lung, match, matching, maximum, member, minimal, mitigate, mitigating, multiple, national, negative, negatively, nonrecurring, notified, orderly, organ, Organization, outbreak, PA, paid, pandemic, partnering, past, path, pausing, preliminary, prolonged, protocol, qualify, quickly, quoted, rapidly, recoup, regional, remotely, resistance, resource, respiratory, response, resumption, revised, role, shock, shorten, site, spiked, spread, staffing, submission, supply, supplying, suspended, Syndrome, transfer, Translational, ultimately, Unadjusted, uncertain, unfavorable, unfold, unforeseen, unobservable, unprecedented, unregistered, unrestricted, UVA, vital, Wainwright, widespread, worker, World, worsening
Removed:
acquisition, adjustment, approach, approximate, arising, assessment, assuming, behalf, carry, carryforward, Certificate, classification, comparability, condensed, decreased, derivative, Distinguishing, doubt, effected, enabling, entitled, entity, fall, feature, February, fifteen, fractional, freestanding, Hedging, Incorporation, indexed, instrument, investor, modified, objective, obstacle, payment, permanent, practical, prescribed, previously, prominent, Proportional, puttable, realization, reclassified, recognition, redeemable, requiring, retroactive, retrospective, reverse, rounded, satisfaction, security, single, split, thereof, transparency
Financial reports
10-Q
2020 Q1
Quarterly report
11 May 20
10-K
2019 FY
Annual report
17 Mar 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
19 Mar 19
10-Q
2018 Q3
Quarterly report
13 Nov 18
10-Q
2018 Q2
Quarterly report
10 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
10-K
2017 FY
Annual report
2 Apr 18
Current reports
8-K
Phase 1b dosing expected to begin this month
7 Jul 20
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 20
8-K
Dosing expected to begin in Q2 2020 with first data in Q3 2020
12 Jun 20
8-K
Other Events
1 Jun 20
8-K
Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program
26 May 20
8-K
Other Events
20 May 20
8-K
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
20 May 20
8-K
Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
11 May 20
8-K
Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS
8 May 20
8-K
Entry into a Material Definitive Agreement
6 May 20
Registration and prospectus
424B3
Prospectus supplement
8 Jun 20
S-1/A
IPO registration (amended)
3 Jun 20
S-1
IPO registration
29 May 20
D
$750K in options / securities to be acquired, sold $750K, 4 investors
27 May 20
424B5
Prospectus supplement for primary offering
19 May 20
D
$625K in options / securities to be acquired, sold $625K, 1 investor
15 May 20
S-8
Registration of securities for employees
13 May 20
424B3
Prospectus supplement
30 Dec 19
S-1
IPO registration
20 Dec 19
D
$783.35K in options / securities to be acquired, sold $783.35K, 3 investors
17 Dec 19
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
PRE 14A
Preliminary proxy
17 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
DEFA14A
Additional proxy soliciting materials
30 Apr 18
DEF 14A
Definitive proxy
30 Apr 18
PRE 14A
Preliminary proxy
20 Apr 18
DEF 14A
Definitive proxy
18 Sep 17
PRE 14A
Preliminary proxy
8 Sep 17
Other
EFFECT
Notice of effectiveness
11 Jun 20
EFFECT
Notice of effectiveness
30 Dec 19
EFFECT
Notice of effectiveness
14 Nov 19
CORRESP
Correspondence with SEC
8 Nov 19
CORRESP
Correspondence with SEC
30 Oct 19
CORRESP
Correspondence with SEC
28 Oct 19
CORRESP
Correspondence with SEC
28 Oct 19
UPLOAD
Letter from SEC
22 Oct 19
EFFECT
Notice of effectiveness
9 Oct 19
CORRESP
Correspondence with SEC
4 Oct 19
Ownership
4
Diffusion Pharmaceuticals / Robert W Adams ownership change
18 Jun 20
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
18 Jun 20
4
Diffusion Pharmaceuticals / Mark T Giles ownership change
18 Jun 20
4
Diffusion Pharmaceuticals / ALAN G LEVIN ownership change
18 Jun 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Diffusion Pharmaceuticals Inc.
14 Feb 20
4
Diffusion Pharmaceuticals / John Gainer ownership change
30 Jan 20
4
Diffusion Pharmaceuticals / David G Kalergis ownership change
30 Jan 20
4
Diffusion Pharmaceuticals / William Karl Hornung ownership change
30 Jan 20
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
13 Jan 20